8 results on '"Martín-Ozaeta G"'
Search Results
2. [The social and work-related impact of multiple sclerosis]
- Author
-
Martínez Yélamos S, Martínez Yélamos A, Jj, Hernández Regadera, Martín Ozaeta G, and Arbizu Urdiain T
- Subjects
Adult ,Employment ,Male ,Multiple Sclerosis ,Surveys and Questionnaires ,Disease Progression ,Humans ,Social Support ,Architectural Accessibility ,Female ,Middle Aged - Abstract
To analyse the repercussion of the disease in social and occupational status of multiple sclerosis patients. To describe the frequency with these patients are faced to architectural barriers in their own home.We addressed a postal survey to 250 patients previously evaluated in our multiple sclerosis unit. Clinical data were recorded in the EDMUS database.A hundred and sixty patients answered the questionnaire. Mean age was 39.2 +/- 11.9 years. Mean duration of the disease was 10.05 +/- 8.4 years. Twenty-one per cent of patients were in progressive phase of the disease. Eighty-nine patients (55.6%) were unemployed. Unemployed patients had arrived to a moderate disability level (EISor = 3) before than employed patients. Only 17% of patients older than 50 years were employed vs. 63% of those among 26-35 years. Only EIS and years of school attendance were independently related to the unemployment status. Forty per cent of patients referred household income greater to $8,000/year. Thirty-six per cent of patients with severe disability (EIS6) was living in a floor with stairs and without lift. Forty-four per cent of patients with EIS6 had architectural barriers in their bathroom.More than half of multiple sclerosis patients were unemployed. Only the degree of disability and educational level were related in a independent way with unemployment status. Many patients unable to walking unaided had architectural barriers at home.
- Published
- 1999
3. Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.
- Author
-
Meca-Lallana JE, Prieto González JM, Caminero Rodríguez AB, Olascoaga Urtaza J, Alonso AM, Durán Ferreras E, Espinosa R, Dotor J, Romera M, Ares Luque A, Pérez Ruiz D, Calles C, Hernández MA, Hervás García M, Mendoza Rodríguez A, Berdei Montero Y, Téllez N, Herrera Varó N, Sotoca J, Presas-Rodríguez S, Querol Gutierrez LA, Hervás Pujol M, Batlle Nadal J, Martín Ozaeta G, Gubieras Lillo L, Martínez Yélamos S, Ramió-Torrentà L, Mallada Frechin J, Belenguer Benavides A, Gascón-Giménez F, Casanova B, Landete Pascual L, Berenguer L, Navarro L, Gómez Gutierrez M, Durán C, Rodríguez Regal A, Álvarez E, García-Estévez DA, López Real AM, Llaneza González MA, Marzo Sola ME, Sánchez-Menoyo JL, Oterino A, Villaverde González R, Castillo-Triviño T, Álvarez de Arcaya A, and Llarena C
- Abstract
Introduction: Teriflunomide is a once-daily oral immunomodulator approved for relapsing forms of multiple sclerosis (MS) or relapsing-remitting multiple sclerosis (RRMS; depending on the local label), based on extensive evidence from clinical trials and a real-world setting on efficacy, tolerability and patient-reported benefits. The TERICARE study assessed the impact of teriflunomide treatment over 2 years on health-related quality of life (HRQoL) and some of the most common and disabling symptoms of MS, such as fatigue and depression., Methods: This prospective observational study in Spain included RRMS patients treated with teriflunomide for ≤ 4 weeks. The following patient-reported outcomes (PROs) were collected at baseline and every 6 months for 2 years: the 29-item Multiple Sclerosis Impact Scale version 2 (MSIS-29), the 21-item Modified Fatigue Impact Scale (MFIS-21), the Beck Depression Inventory (BDI-II), the Short Form (SF)-Qualiveen and the Treatment Satisfaction Questionnaire for Medication v1.4 (TSQM). Annualised relapse rate (ARR), disability progression according to the Expanded Disability Status Scale (EDSS), and no evidence of disease activity (NEDA-3) were also assessed., Results: A total of 325 patients were analysed. Patients had a mean (SD) age of 43.2 years (10.4), a mean baseline EDSS score of 1.75 (1.5), a mean number of relapses in the past 2 years of 1.5 (0.7), and 64% had received prior disease-modifying therapy (DMT). Patients showed significant improvements in the psychological domain of MSIS-29 from 35.9 (26.6) at baseline to 29.4 (25.5) at 18 months (p = 0.004) and 29.0 (24.6) at 24 months (p = 0.002). Levels of fatigue and depression were also reduced. After 2 years of treatment with teriflunomide, ARR was reduced to 0.17 (95% CI 0.14-0.21) from the baseline of 0.42 (95% CI 0.38-0.48), representing a 60.1% reduction. Mean EDSS scores remained stable during the study, and 79.9% of patients showed no disability progression. 54.7% of patients achieved NEDA-3 in the first 12 months, which increased to 61.4% during months 12-24. Patients reported increased satisfaction with treatment over the course of the study, regardless of whether they were DMT naive or not., Conclusion: Teriflunomide improves psychological aspects of HRQoL and maintains low levels of fatigue and depression. Treatment with teriflunomide over 2 years is effective in reducing ARR and disability progression., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
4. Vascular Risk Factors in Ischemic Stroke Survivors: A Retrospective Study in Catalonia, Spain.
- Author
-
Reverté-Villarroya S, Suñer-Soler R, Zaragoza-Brunet J, Martín-Ozaeta G, Esteve-Belloch P, Payo-Froiz I, Sauras-Colón E, and Lopez-Espuela F
- Abstract
Background: The distribution of vascular risk factors (VRFs) and stroke management vary by geographic area. Our aim was to examine the percentage of the VRFs according to age and sex in ischemic stroke survivors in a geographical area on the Mediterranean coast of Southern Catalonia, Spain. Methods: This was a multicenter, observational, retrospective, community-based study of a cohort, the data of which we obtained from digital clinical records of the Catalan Institute of Health. The study included all patients with a confirmed diagnosis of ischemic stroke who were treated between 1 January 2011 and 31 December 2020. Patients met the following inclusion criteria: residing in the study area, age ≥ 18 years, and presenting ≥1 modifiable vascular risk factor. The exclusion criteria were as follows: death patients (non-survivors) and patients without modifiable VRFs. We collected the demographic, clinical, and VRF variables of the total of 2054 cases included, and we analyzed the data according to age groups, sex, and number of VRFs. Results: Most of the patients included were in the 55−80 age group (n = 1139; 55.45%). Of the patients, 56.48% (n = 1160) presented ≤ 2 modifiable VRFs, and the age group <55 years old (67.01%) presented more VRFs. Hypertension and (>80 years old (38.82%)) and dyslipidemia (<55 years (28.33%)) were the most prevalent VRFs. In the age group 55−80 (69.59% men), the prevalence of VRFs was higher ((3−4 VRF (42.76%) and >4 VRF (5.35%)). Conclusions: These results suggest the presence of many VRFs in people diagnosed with ischemic stroke—although with a lower percentage compared to other studies—and the need for specific individualized interventions for the control of modifiable RFs related to primary and secondary prevention of stroke.
- Published
- 2022
- Full Text
- View/download PDF
5. Apolipoprotein alleles and the response to interferon-β-1b in multiple sclerosis.
- Author
-
Carmona O, Masuet C, Alía P, Moral E, Alonso-Magdalena L, Casado V, Martín-Ozaeta G, and Arbizu T
- Subjects
- Adult, Alleles, Disability Evaluation, Female, Genetic Predisposition to Disease, Genotype, Humans, Longitudinal Studies, Male, Prognosis, Prospective Studies, Severity of Illness Index, Treatment Outcome, Apolipoproteins E genetics, Immunologic Factors therapeutic use, Interferon-beta therapeutic use, Multiple Sclerosis genetics, Multiple Sclerosis therapy
- Abstract
Background: Results for the e4/e2 alleles of the ApoE gene as markers of susceptibility, clinical and radiological progression, and cognitive deterioration in patients with multiple sclerosis (MS) are contradictory., Aim: The usefulness of these markers in predicting the response to interferon-β-1b (IFNβ-1b) was evaluated., Material and Methods: 95 patients with relapsing-remitting MS treated with IFNβ-1b (mean follow-up 7.44 years) were studied. We correlated the e4 and e2 alleles with the time to the first relapse or to a 1-point worsening on the Expanded Disability Status Scale, time to moderate disability, progression index, and treatment discontinuation due to inefficacy., Results: We found no association between the e4 allele and any of the variables. The e2 allele was associated with increased time to moderate disability., Conclusion: The e4 allele of ApoE has no prognostic value for the response to IFNβ-1b. The e2 allele delayed the progression of disability in our MS patient cohort., (Copyright © 2011 S. Karger AG, Basel.)
- Published
- 2011
- Full Text
- View/download PDF
6. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
- Author
-
Carmona O, Casado V, Moral E, Alonso-Magdalena L, Martínez-Yélamos A, Martínez-Yélamos S, Martín-Ozaeta G, and Arbizu T
- Subjects
- Adult, Disability Evaluation, Disease Progression, Female, Humans, Interferon beta-1b, Male, Medication Adherence, Recurrence, Treatment Outcome, Adjuvants, Immunologic therapeutic use, Interferon-beta therapeutic use, Multiple Sclerosis, Relapsing-Remitting drug therapy
- Abstract
There is limited long-term data on the effect of interferon-beta1b (IFN-beta1b) on disability progression in patients with multiple sclerosis (MS). There is also no reliable way of predicting individual responses to IFN-beta1b treatment. This prospective study investigated early clinical prognostic markers of disease activity and progression in 115 patients with relapsing-remitting MS (RRMS) treated with IFN-beta1b for almost 5 years. The study also compared progression of disability in IFN-beta1b-treated patients with a historic untreated cohort of MS patients (n = 44). The number of relapses in the first 2 years of MS and in the 2 years before treatment predicted an early relapse after IFN-beta1b treatment. The IFN-beta1b-treated group experienced a slower progression of disability than the untreated cohort, suggesting that IFN-beta1b treatment delays progression of disability in RRMS., (Copyright 2008 S. Karger AG, Basel.)
- Published
- 2008
- Full Text
- View/download PDF
7. Regression to the mean in multiple sclerosis.
- Author
-
Martínez-Yélamos S, Martínez-Yélamos A, Martín Ozaeta G, Casado V, Carmona O, and Arbizu T
- Subjects
- Adjuvants, Immunologic therapeutic use, Adult, Data Interpretation, Statistical, Disability Evaluation, Follow-Up Studies, Humans, Multiple Sclerosis, Relapsing-Remitting drug therapy, Prospective Studies, Randomized Controlled Trials as Topic, Recurrence, Multiple Sclerosis, Relapsing-Remitting epidemiology, Placebo Effect, Regression Analysis
- Abstract
In order to ensure sufficient disease activity, patients with relapsing remitting (RR) multiple sclerosis (MS) are often included in randomized placebo-controlled trials, only if they have a high baseline activity. These patients, whose evolution is unusual in the pre-study period, will tend to show a more usual behavior when followed up over a period of time. This phenomenon is known as regression to the mean. Regression to the mean should be taken into account in correctly interpreting long-term studies of cohorts treated without a placebo control group, which use the baseline period as control. The aim of this study was to evaluate the relevance of this phenomenon in a non-treated cohort of RRMS patients, selected with similar criteria to those used in randomized placebo-controlled clinical trials. Forty-four patients with definite RRMS, with two or more relapses in the previous two years, and a baseline EDSS < or = 5.5 were prospectively followed. The mean number of relapses spontaneously decreased from 1.72 (SD: 1.4) in the year prior to enrolment, to 1.0 (SD: 1.3) during the first year of follow-up (P < 0.05). Regression to the mean may explain as much as 40% of the reduction in the relapse rate from the baseline period to the period on-study.
- Published
- 2006
- Full Text
- View/download PDF
8. [Evolution of the demand for ambulatory neurological care and pathologies attended in neurology clinics in the health care district of Tortosa, Tarragona].
- Author
-
Huerta-Villanueva M, Baiges-Octavio JJ, Martín-Ozaeta G, Muñoz-Farjas E, and Rubio-Borrego F
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Ambulatory Care trends, Cerebrovascular Disorders epidemiology, Child, Cognition Disorders epidemiology, Diagnosis-Related Groups, Female, Humans, Male, Middle Aged, Migraine Disorders epidemiology, Nervous System Diseases diagnosis, Nervous System Diseases therapy, Prospective Studies, Spain epidemiology, Ambulatory Care statistics & numerical data, Health Services Needs and Demand trends, Nervous System Diseases epidemiology, Neurology
- Abstract
Aims: An analysis was conducted to determine whether there were any changes in the demand for health care, demography and pathologies attended in outpatient departments within the health care district of Tortosa between 1997 and 2003., Patients and Methods: Data about the demand for and attendance at first neurology visits over the period 1997 and from March 2003 to February 2004 was collected prospectively. Information concerning age, sex, groups of pathologies, diagnoses, rates of requests for first visits, source of the demand and destination after the visit were compared., Results: Mean age rose from 49 to 56 years (p < 0.001). Patients above 70 years of age increased from 23.7% to 35.9% (p < 0.001), while in the population within the area the figure only rose from 15.8 to 17.1%. The proportion of females went up from 52 to 62% (p < 0.001). Demand (that is, the rate of requests for first visits per 1000 inhabitants per year among those over the age of 15) rose from 8.5 to 9.3, 9.8% (p = 0.03). Demand from primary care increased from 52 to 69% (p < 0.001). Cognitive disorders (6.5% and 15.9%) grew by 144.6% (p < 0.001). Headaches (23.9% and 24.1%), the largest diagnostic group, and non-neurological diagnoses (18% and 18.5%) remained unchanged (p = NS). No changes were observed in the number of discharges in the first visit: 22.8% and 21.1% (p = NS)., Conclusions: The most striking results are the increase in demand (mainly from primary care), the increased age of the population attended and the notable growth in the number of cognitive disorders. These quantitative and qualitative changes in the demand increase the need for resources.
- Published
- 2005
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.